Cancers, Vol. 13, Pages 3958: Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice

The objective response rate (ORR) at six weeks after the start of treatment, changes in α-fetoprotein (AFP) and des-γ-carboxyprothrombin, incidence of adverse events (AEs), and changes in albumin-bilirubin (ALBI) score and serum ammonia level, were evaluated. Among 40 patients, 24 had histories of prior molecular targeted agents (MTAs). The ORR was 22.5% based on mRECIST. Multivariate analysis showed that an AFP ratio <1.0 at three weeks (odds ratio 39.2, 95% confidence interval CI 2.37–649.0, p = 0.0103) was the only significant factor for predicting early response. There was no significant difference in the frequency of AEs between patients receiving first-line treatments and others. Fatigue, proteinuria, and ascites were more frequent in patients who experienced prior treatment. No decrease in ALBI score or increase in serum ammonia level was observed. Our study demonstrated that AFP may be useful in assessing early response and that this treatment is safe, including in patients with prior MTA treatments.

Source: Cancers - August 5, 2021 Category: Cancer & Oncology Authors: Yuwa Ando Tomokazu Kawaoka Masanari Kosaka Yuki Shirane Yusuke Johira Ryoichi Miura Serami Murakami Shigeki Yano Kei Amioka Kensuke Naruto Yumi Kosaka Shinsuke Uchikawa Kenichiro Kodama Hatsue Fujino Takashi Nakahara Atsushi Ono Eisuke Murakami Masami Yam Tags: Article Source Type: research